Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
MBOT
$2.5562
$
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Next Earnings
2026-02-25
Beta
1.289
Average Volume
Market Cap
Last Dividend
CIK
0000883975
ISIN
US59503A2042
CUSIP
59503A204
CEO
Harel Gadot
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Full Time Employees
20
IPO Date
1992-03-25
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Tampa General Hospital Adopts Small-Cap Microbot Medical's Robotic System | Microbot Medical's recent achievement comes on the heels of its FDA 510(k) clearance for the LIBERTY system, which is designed for precision in peripheral endovascular procedures. | Benzinga | 2026-02-24 13:48:59 |
| Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System | HINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking another important milestone following the Company's recent FDA 510(k) clearance. | GlobeNewsWire | 2026-02-24 08:30:00 |
| Microbot Medical®'s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference | Microbot Medical®'s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference | GlobeNewsWire | 2026-02-19 08:30:00 |
| Microbot Medical®'s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference | International Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics LIBERTY® Continues to Gain Commercial Traction and Exposure as Part of Its Limited Market Release (LMR) in the US HINGHAM, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that LIBERTY was featured at the International Symposium on Endovascular Therapy (ISET) conference, which took place February 9-12, 2026, in Miami Beach, Florida. | GlobeNewsWire | 2026-02-12 08:30:00 |
| Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption | HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. | GlobeNewsWire | 2026-02-05 08:30:00 |
| Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones | Limited Market Release (LMR) of the LIBERTY® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 HINGHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is continuing to generate significant market and new customer momentum as it enters 2026. | GlobeNewsWire | 2026-01-12 08:30:00 |
| Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System | HINGHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University Hospital, a nationally recognized academic medical center in Atlanta, has become the first hospital to adopt LIBERTY for patient care. | GlobeNewsWire | 2025-11-26 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-24 | 2026-02-24 | View Filing |
| 8-K | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 8-K | 2026-02-19 | 2026-02-19 | View Filing |
| 8-K | 2026-02-12 | 2026-02-12 | View Filing |
| 8-K | 2026-02-05 | 2026-02-05 | View Filing |
| SC 13G | 2026-01-23 | 2026-01-23 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2025-11-26 | 2025-11-26 | View Filing |
| 424B3 | 2025-11-19 | 2025-11-19 | View Filing |
| 424B3 | 2025-11-19 | 2025-11-19 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G/A | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| SC 13G/A | 2025-10-31 | 2025-10-31 | View Filing |
| S-3/A | 2025-10-28 | 2025-10-28 | View Filing |
| S-3/A | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-10-16 | 2025-10-16 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| S-3 | 2025-10-14 | 2025-10-14 | View Filing |
| S-3 | 2025-10-14 | 2025-10-14 | View Filing |
| 8-K | 2025-10-07 | 2025-10-07 | View Filing |
| 8-K | 2025-10-03 | 2025-10-03 | View Filing |
| 8-K | 2025-10-01 | 2025-10-01 | View Filing |
| D | 2025-09-30 | 2025-09-29 | View Filing |
| 8-K | 2025-09-23 | 2025-09-23 | View Filing |
| 8-K | 2025-09-19 | 2025-09-19 | View Filing |
| 8-K | 2025-09-16 | 2025-09-16 | View Filing |
| 8-K | 2025-09-09 | 2025-09-09 | View Filing |
| 8-K | 2025-09-08 | 2025-09-08 | View Filing |
| 8-K | 2025-08-27 | 2025-08-27 | View Filing |
| 8-K | 2025-08-25 | 2025-08-25 | View Filing |
| 8-K | 2025-08-20 | 2025-08-20 | View Filing |
| SC 13G/A | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-07-30 | 2025-07-30 | View Filing |
| SC 13G | 2025-07-29 | 2025-07-29 | View Filing |
| S-8 | 2025-07-21 | 2025-07-22 | View Filing |
| 8-K | 2025-07-22 | 2025-07-22 | View Filing |
| 8-K | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-07-08 | 2025-07-08 | View Filing |
| 8-K | 2025-06-30 | 2025-06-30 | View Filing |
| 8-K | 2025-06-17 | 2025-06-17 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| 8-K | 2025-06-09 | 2025-06-09 | View Filing |
| 8-K | 2025-06-05 | 2025-06-05 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| SC 13G/A | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-04-30 | 2025-04-30 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| ARS | 2025-04-29 | 2025-04-29 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-23 | 2025-04-23 | View Filing |
| PRE 14A | 2025-04-17 | 2025-04-18 | View Filing |
| 8-K | 2025-04-17 | 2025-04-17 | View Filing |
| 8-K | 2025-04-15 | 2025-04-15 | View Filing |
| 8-K | 2025-04-09 | 2025-04-09 | View Filing |
| 424B3 | 2025-04-08 | 2025-04-08 | View Filing |
| 424B3 | 2025-04-08 | 2025-04-08 | View Filing |
| 424B3 | 2025-04-08 | 2025-04-08 | View Filing |
| 424B3 | 2025-04-08 | 2025-04-08 | View Filing |
| 424B3 | 2025-04-03 | 2025-04-03 | View Filing |
| EFFECT | 2025-04-03 | 2025-04-03 | View Filing |
| EFFECT | 2025-04-03 | 2025-04-03 | View Filing |
| EFFECT | 2025-04-03 | 2025-04-03 | View Filing |
| EFFECT | 2025-04-03 | 2025-04-03 | View Filing |
| EFFECT | 2025-04-02 | 2025-04-02 | View Filing |
| 8-K | 2025-04-01 | 2025-04-01 | View Filing |
| POS AM | 2025-03-31 | 2025-03-31 | View Filing |
| POS AM | 2025-03-31 | 2025-03-31 | View Filing |
| POS AM | 2025-03-28 | 2025-03-28 | View Filing |
| POS AM | 2025-03-27 | 2025-03-27 | View Filing |
| POS AM | 2025-03-27 | 2025-03-27 | View Filing |
| S-3/A | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-25 | 2025-03-25 | View Filing |
| S-3 | 2025-03-10 | 2025-03-10 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| DEFA14A | 2025-02-28 | 2025-02-28 | View Filing |
| DEF 14A | 2025-02-28 | 2025-02-28 | View Filing |
| 8-K | 2025-02-25 | 2025-02-25 | View Filing |
| 424B3 | 2025-02-21 | 2025-02-21 | View Filing |
| PRE 14A | 2025-02-18 | 2025-02-18 | View Filing |
| D | 2025-02-18 | 2025-02-18 | View Filing |
| EFFECT | 2025-02-14 | 2025-02-14 | View Filing |
| 424B3 | 2025-02-12 | 2025-02-12 | View Filing |
| 424B3 | 2025-02-12 | 2025-02-12 | View Filing |
| 8-K | 2025-02-12 | 2025-02-11 | View Filing |
| 8-K | 2025-02-11 | 2025-02-11 | View Filing |
| 424B5 | 2025-02-11 | 2025-02-11 | View Filing |
| S-1/A | 2025-02-10 | 2025-02-10 | View Filing |
| 424B3 | 2025-02-10 | 2025-02-10 | View Filing |
| 424B3 | 2025-02-10 | 2025-02-10 | View Filing |
| 424B3 | 2025-02-10 | 2025-02-10 | View Filing |
| 424B3 | 2025-02-10 | 2025-02-10 | View Filing |
| 8-K | 2025-02-10 | 2025-02-10 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Swarm Intelligence Strategy | 27.49% | 1.06 | 39 | 0.63 | 0.56 | 28.79 |
| Keltner Channel Strategy | 14.77% | 1.52 | 23 | 0.52 | 0.58 | 16.07 |
| Price Action Strategy | 13.62% | 1.49 | 7 | 0.36 | 0.3 | 14.92 |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxx | xxxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xx | xxxxx | xxxxx |